News Sentiment

CVKD sentiment intelligence

Cadrenal Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.89 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 56

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

-19.7% over one week, -21.9% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Cadrenal Therapeutics (CVKD) outlines $8.84M Rule 506(b) warrant financing

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction -19.7% Price reacting lower
Trend fit Trend inactive -21.9% over four weeks
Fair value -73.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 38
Negative 12

Relevance

Why the article matched

Direct first
Direct company coverage 56
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
Market source 8
GlobeNewswire 7
Investing.com 5
TradingView 5
Quiver Quantitative 4
MT Newswires 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 40
Earnings 17
Balance sheet 2
Deals and strategy 2
Guidance 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 63
Stock Titan Direct company coverage

Cadrenal Therapeutics (CVKD) outlines $8.84M Rule 506(b) warrant financing

Cadrenal Therapeutics, Inc. has filed a notice for an exempt private offering under Rule 506(b) of Regulation D, involving options and warrants totaling $8.84 million. H.C. Wainwright & Co., LLC served as the placement agent, receiving fees and warrants for their services. The pr

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

Cadrenal Therapeutics (NASDAQ: CVKD) files resale for 2.94M warrant shares

Cadrenal Therapeutics has filed to register for resale up to 2.94 million shares of common stock, which includes shares associated with pre-funded, Series C-1, and Series C-2 warrants from a recent PIPE financing, as well as placement agent warrants. The company will not receive

Tone
Negative 34/100
Event
Market update
Published
13 Jul 2026 21:10
Source
Stock Titan
GlobeNewswire Direct company coverage

Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress

Cadrenal Therapeutics announced late-breaking Phase 2 clinical data for its 12-LOX inhibitor CAD-1005, showing a greater than 25% reduction in thrombotic events in patients with Heparin-Induced Thrombocytopenia (HIT). The data, presented at the ISTH 2026 Congress, highlighted CAD

Tone
Positive 72/100
Event
Market update
Published
13 Jul 2026 12:41
Source
GlobeNewswire
Investing.com Direct company coverage

Cadrenal presents phase 2 data for CAD-1005 at ISTH congress

Cadrenal Therapeutics presented Phase 2 clinical trial data for CAD-1005, a 12-lipoxygenase inhibitor, at the ISTH Congress, showing a reduction in thrombotic events for HIT patients. Despite positive clinical outcomes and the drug being Phase 3-ready with FDA Orphan Drug and Fas

Tone
Negative 40/100
Event
Market update
Published
13 Jul 2026 12:41
Source
Investing.com
Stock Titan Direct company coverage

Cadrenal Therapeutics (CVKD) Chief Medical Officer James Ferguson to step down July 31, 2026

Cadrenal Therapeutics announced that its Chief Medical Officer, Dr. James J. Ferguson III, will resign effective July 31, 2026. The company is actively searching for a replacement and is negotiating separation terms with Dr. Ferguson. This transition introduces potential leadersh

Tone
Negative 38/100
Event
Market update
Published
10 Jul 2026 19:40
Source
Stock Titan
www.marketscreener.com Direct company coverage

Cadrenal Therapeutics, Inc. Announces Resignation of James J. Ferguson III from Chief Medical Officer Role, Effective July 31, 2026

Cadrenal Therapeutics, Inc. announced the resignation of James J. Ferguson III from his position as Chief Medical Officer, effective July 31, 2026. Dr. Ferguson advised the Board of Directors of his decision on July 7, 2026. The company is actively searching for a replacement and

Tone
Negative 39/100
Event
Market update
Published
10 Jul 2026 14:09
Source
www.marketscreener.com
Investing.com Direct company coverage

Cadrenal Therapeutics CEO sells $22,422 in stock

Cadrenal Therapeutics CEO Pham Quang X sold 7,400 shares of company stock worth $22,422 on June 29, 2026, under a pre-arranged trading plan. Despite the insider sale and a significant year-over-year stock price drop, InvestingPro analysis suggests the stock is undervalued. The co

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 00:11
Source
Investing.com
The Globe and Mail Direct company coverage

Cadrenal Therapeutics Secures Private Placement to Extend Runway

Cadrenal Therapeutics has secured a private placement of shares and warrants, raising approximately $3 million upfront with the potential for an additional $5.8 million if warrants are fully exercised. This financing is expected to extend the company's cash runway into early 2027

Tone
Neutral 50/100
Event
Balance sheet
Published
02 Jul 2026 21:39
Source
The Globe and Mail
Stock Titan Direct company coverage

Cadrenal (CVKD) CEO sells 7,400 shares, retains direct and trust stakes

Cadrenal Therapeutics (CVKD) Chairman and CEO Quang Pham sold 7,400 shares of common stock at a weighted average price of $3.03 per share on June 29, 2026, under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, Pham directly holds 98,589 shares and indirectly o

Tone
Negative 39/100
Event
Market update
Published
02 Jul 2026 03:09
Source
Stock Titan
TradingView Direct company coverage

Cadrenal Therapeutics Raises $3.0 Million in Private Placement of Pre-Funded and Common Warrants

Cadrenal Therapeutics has raised $3.0 million through a private placement involving pre-funded and common warrants with an institutional investor. The funds will be used for working capital. The company also entered into a Registration Rights Agreement to facilitate the resale of

Tone
Positive 72/100
Event
Market update
Published
01 Jul 2026 21:40
Source
TradingView
Stock Titan Direct company coverage

Cadrenal Therapeutics (NASDAQ: CVKD) lines up up to $8.8M via private placement

Cadrenal Therapeutics announced a private placement deal with an institutional investor, expected to generate $3 million in gross proceeds upfront and potentially an additional $5.8 million from warrant exercises, totaling up to $8.8 million. The funds are earmarked for working c

Tone
Positive 65/100
Event
Deals and strategy
Published
01 Jul 2026 21:40
Source
Stock Titan
Market source Direct company coverage

Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Cadrenal Therapeutics Inc. announced a private placement priced at-the-market under Nasdaq rules, potentially raising up to $8.8 million. The offering includes $3 million upfront from the sale of common stock and warrants, with an additional $5.8 million possible if the warrants

Tone
Positive 63/100
Event
Market update
Published
01 Jul 2026 12:10
Source
Market source
Stock Titan Direct company coverage

Cadrenal raises $3M now, with $5.8M more possible from warrants

Cadrenal Therapeutics announced a private placement to raise $3 million upfront from the sale of common shares and warrants, with the potential for an additional $5.8 million if all warrants are fully exercised. The company expects the initial proceeds to extend its cash runway i

Tone
Neutral 50/100
Event
Guidance
Published
01 Jul 2026 12:10
Source
Stock Titan
RTTNews Direct company coverage

Cadrenal Therapeutics Enters Upto $8.8 Mln Private Placement To Extend Cash Runway; Stock Down

Cadrenal Therapeutics announced a private placement offering of shares and warrants expected to raise $3 million initially, with potential additional proceeds of $5.8 million, to extend its cash runway. This news caused the company's stock (CVKD) to plunge over 11% in pre-market

Tone
Negative 28/100
Event
Balance sheet
Published
01 Jul 2026 06:38
Source
RTTNews
Investing.com Direct company coverage

Cadrenal Therapeutics raises $3 million in private placement

Cadrenal Therapeutics, Inc. has raised $3 million through a private placement with a healthcare-focused institutional investor. The biopharmaceutical company will issue 960,000 shares or pre-funded warrants, with potential additional proceeds of $5.8 million if all accompanying w

Tone
Positive 74/100
Event
Market update
Published
01 Jul 2026 00:39
Source
Investing.com
Moomoo Direct company coverage

Cadrenal Therapeutics Names Sharp Interim CFO

Cadrenal Therapeutics has appointed Brian Sharp as its interim Chief Financial Officer, effective immediately. Sharp, previously a partner at the accounting firm BDO and having experience with public biotech companies, steps into the role after the resignation of the previous CFO

Tone
Negative 42/100
Event
Market update
Published
29 Jun 2026 22:39
Source
Moomoo
Stock Titan Direct company coverage

Cadrenal Therapeutics (NASDAQ: CVKD) names interim CFO and realigns board classes

Cadrenal Therapeutics appointed John P. Sharp as interim Chief Financial Officer, replacing Quang X. Pham, who remains Chairman and CEO. Sharp will provide services via Lohman & Associates at $455/hour for up to 24 hours weekly. Additionally, director Steven Zelenkofske resigned,

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 21:20
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 4 Cadrenal Therapeutics Inc For: 26 June By Investing.com

This article reports on a Form 4 filing for Cadrenal Therapeutics Inc (CVKD) dated June 26. It indicates that the company's stock symbol is CVKD and provides its price performance at the time of publication. The document itself seems to be a brief announcement of the regulatory f

Tone
Neutral 50/100
Event
Regulatory and legal
Published
27 Jun 2026 21:39
Source
Investing.com Nigeria
Investing.com South Africa Direct company coverage

Cadrenal therapeutics CEO Pham sells $33,919 in stock By Investing.com

Cadrenal Therapeutics CEO Quang X. Pham sold 11,156 shares of the company's common stock for a total of $33,919, executed under a Rule 10b5-1 trading arrangement. These sales occurred on June 25th and 26th, 2026, as the stock experienced a 13% decline over the past week. Despite

Tone
Negative 37/100
Event
Market update
Published
27 Jun 2026 08:10
Source
Investing.com South Africa
TradingView Direct company coverage

Price to earnings forward of Cadrenal Therapeutics, Inc. – NASDAQ:CVKD

This article provides financial information for Cadrenal Therapeutics, Inc. (NASDAQ: CVKD), specifically focusing on its "Price to earnings forward" metric. The content appears to be a financial data page from TradingView, offering an overview of the company's financials, news, a

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 06:39
Source
TradingView
Stock Titan Direct company coverage

Cadrenal Therapeutics (CVKD) CEO Quang Pham sells 11,156 shares under 10b5-1 plan

Cadrenal Therapeutics' CEO and Chairman, Quang X. Pham, reported selling 11,156 shares of common stock in late June 2026 under a pre-arranged Rule 10b5-1 trading arrangement adopted in September 2025. The sales were executed in two transactions at prices of $3.00 and a weighted a

Tone
Negative 38/100
Event
Market update
Published
27 Jun 2026 01:39
Source
Stock Titan
Investing.com Direct company coverage

Cadrenal Therapeutics chairman and CEO Pham sells $39,829 in stock.

Cadrenal Therapeutics' Chairman, CEO, and Interim CFO Pham Quang X sold shares worth $39,829 under a Rule 10b5-1 trading plan. The sales occurred on June 22nd and 23rd, 2026, at weighted average prices of $3.55 and $3.20 respectively, following a 73% decline in the company's stoc

Tone
Negative 37/100
Event
Market update
Published
24 Jun 2026 23:41
Source
Investing.com
Stock Titan Direct company coverage

Cadrenal (CVKD) CEO Quang Pham sells 11,444 shares in planned 10b5-1 trades

Cadrenal Therapeutics CEO and Chairman Quang Pham sold 11,444 shares of common stock in June 2026 under a pre-arranged Rule 10b5-1 trading plan adopted in September 2025. The sales, totaling approximately $39,829, were open-market transactions at weighted average prices of $3.55

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 21:41
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 4 Cadrenal Therapeutics Inc For: 24 June By Investing.com

This article reports on a Form 4 filing for Cadrenal Therapeutics Inc. on June 24th. The filing indicates insider trading activity for the company. The stock symbol associated with Cadrenal Therapeutics Inc. is CVKD.

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 21:41
Source
Investing.com Canada